Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.57 USD | -0.68% | -1.28% | -32.46% |
05-09 | Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating | MT |
05-09 | B. Riley Downgrades Viridian Therapeutics to Neutral From Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.46% | 936M | |
+26.03% | 49.18B | |
+0.88% | 42.11B | |
+50.07% | 40.37B | |
-5.26% | 28.85B | |
+13.02% | 26.09B | |
-22.19% | 18.71B | |
+8.35% | 13.26B | |
+31.72% | 12.32B | |
+0.01% | 11.99B |
- Stock Market
- Equities
- VRDN Stock
- News Viridian Therapeutics, Inc.
- RBC Cuts Price Target on Viridian Therapeutics to $35 From $44, Keeps Outperform Rating, Speculative Risk Qualifier